ÂÜÀòÂÒÂ×

John Josey is a venture partner at The Column Group. John has over 25 years of experience in the biotech industry, including leadership roles at Amgen, Atavistik Bio, Inc., and Peloton Therapeutics, Inc.

Josey began their career as a research scientist at Glaxo Inc. in 1991. John joined Amgen in 1995 as a scientist and held that position until 1998. In 2011, they became president and chief scientific officer of Peloton Therapeutics, Inc., and held that role for two years before becoming President and CEO in 2013. John led the company until 2019 when they joined The Column Group as a venture partner.

Josey has been honored to work with The Column Group, Lux Capital, and Nextech Invest to build a great drug-discovery organization in Cambridge, MA. John is particularly delighted that Marion Dorsch, a seasoned drug-hunter, is leading the scientific effort as President & Chief Scientific Officer at Atavistik Bio, Inc.

John Josey earned their B.S. in Chemistry from Colorado State University and their Ph.D. in Organic Chemistry from The University of Texas at Austin. John was a Postdoctoral Fellow at Caltech before earning their MBA in Business Administration from the University of Colorado.

Some of their coworkers include Michael Fischbach - iPartner, Roger Perlmutter - Science Partner, and Jeff Goater - Venture Partner. Their manager is David V. Goeddel, Managing Partner.